pertuzumab

Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.

ORM-5029 is the first antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2), combining the highly potent GSPT1 degrader SMol006 with Pertuzumab. It is applicable in cancer research.

BAT1006 is a monoclonal antibody targeting the extracellular domain II of HER2, with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). It is utilized for research in HER2-positive locally advanced/metastatic solid tumors. Compared to pertuzumab, BAT1006 exhibits roughly 5 times increased ADCC effect and demonstrates potent antitumor activity in HER2-positive Calu-3 xenograft mouse models.